The complement system has recently been described as a crucial component for transplant tolerance induction, but the underlying mechanisms are poorly understood. Using a rodent model of donor lymphocyte infusion-induced male histocompatibility antigen-specific transplant tolerance, we demonstrate that tolerance induction is dependent on the complement receptors decay accelerating factor, complement receptor 3, and complement component 3a receptor (C3aR). Furthermore, we have provided evidence that complement dependent tolerance is mediated through C3aR on infused donor splenocytes and on recipient cells. Ex vivo studies showed that C3aR deficiency leads to an imbalance between T regulatory and T effector cells. Increased numbers of antigen-specific CD8(+) cells in the blood and less T regulatory cells, with reduced suppressive function, in the spleen and in the skin grafts were detected in C3aR deficient compared to wild type mice. This imbalance might be explained by the requirement of complement for dendritic cells to generate T regulatory cells effectively. Our experiments suggest that multiple complement receptors play an important role in transplant tolerance induction providing new insights into the mechanisms of complement dependent tolerance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/tri.12006 | DOI Listing |
Acta Oncol
January 2025
Comprehensive Cancer Center Munich and Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany.
Background: The prognosis of patients with advanced soft tissue sarcoma (STS) remains dismal. Trofosfamide (TRO) has been proposed as a well-tolerated oral maintenance therapy. This retrospective analysis aims to determine the value of this therapy.
View Article and Find Full Text PDFKidney Int Rep
January 2025
Department of Cardiovascular Sciences, University of Leicester, Leicester, Leicestershire, UK.
Introduction: Endothelin A (ETA) receptor activation is a driver of proteinuria, kidney inflammation, and fibrosis in IgA nephropathy (IgAN). Atrasentan, a selective ETA receptor antagonist, has potential to reduce proteinuria and preserve kidney function in IgAN. ALIGN (NCT04573478) is a phase 3, randomized, double-blind, placebo-controlled clinical trial of atrasentan in patients with IgAN at high risk of kidney function loss.
View Article and Find Full Text PDFKidney Int Rep
January 2025
Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Introduction: Complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) have high risks for disease recurrence and allograft loss in transplant kidneys. Pegcetacoplan (targeted complement 3 [C3]/C3b inhibitor) may prevent excessive deposition of C3 and complement 5 [C5] breakdown products and associated renal damage.
Methods: NOBLE (NCT04572854) is a prospective, phase 2, multicenter, open-label, randomized controlled trial evaluating the efficacy and safety of pegcetacoplan in posttransplant patients with recurrent C3G or IC-MPGN.
Transplant Proc
January 2025
Nephrology Department, Hospital Universitario Cruces, Barakaldo, Spain.
Belatacept was introduced as an immunosuppressant for kidney transplantation in 2010, but its use in Spain remains limited. Since its commercialization, 15 kidney transplant recipients have received immunosuppressive treatment with belatacept at the Cruces University Hospital. This observational and retrospective study analyzes the reasons for switching to belatacept, its impact on kidney function, and the drug's safety profile.
View Article and Find Full Text PDFRadiol Case Rep
March 2025
Department of Radiology, University of California-San Francisco, 513 Parnassus Ave, Room S257, Box 0628, San Francisco, CA 94143, USA.
Voriconazole, a triazole antifungal, has proven effective against invasive fungal infections, and is often selected due to its enhanced antifungal spectrum coverage. Despite its general tolerability, voriconazole usage is associated with drug-induced periostitis, which presents with diffuse bone pain. This case report details a 65-year-old male on chronic immunosuppressive and antimicrobial therapy following heart transplant who developed hand pain.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!